75N93020C00018

TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.

National Institutes of Health · United States

This contract has been awarded. Browse open opportunities

View Source

Time Left to Bid

Awarded

AwardedHealthcare & MedicalFederal

Basic information

Reference number: 75N93020C00018
Issuing organization: National Institutes of Health · Find award history →
Government level: Federal
Solicitation type: Healthcare & Medical
Title: TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.
Source: USASpending (Federal)
Source ID: usa-75N93020C00018

Details

Location: United States

Description

TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. Awarded to: REVAGENIX INC Agency: Department of Health and Human Services Sub-agency: National Institutes of Health Award type: DEFINITIVE CONTRACT

Dates

Publication: 2020/07/01 12:00:00 AM UTC
Closing date: 2026/08/31 12:00:00 AM UTC

Estimated value

$26.9M USD

Classification

Normalized category

Healthcare & Medical

Source: USASpending (Federal)

Last updated 2026-07-13, 9:12:19 p.m.

Data refreshed every 2 hours